Limits...
Erythropoietin reduces the expression of myostatin in mdx dystrophic mice.

Feder D, Rugollini M, Santomauro A, Oliveira LP, Lioi VP, Santos Rd, Ferreira LG, Nunes MT, Carvalho MH, Delgado PO, Carvalho AA, Fonseca FL - Braz. J. Med. Biol. Res. (2014)

Bottom Line: EPO exerts regulatory effects in cardiac and skeletal muscles.Total strength was measured using a force transducer coupled to a computer.These results may help to clarify some of the direct actions of EPO on skeletal muscle.

View Article: PubMed Central - PubMed

Affiliation: Faculdade de Medicina do ABC, Santo André, SP, Brasil.

ABSTRACT
Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles. Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. In this study, we tested the possible therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α) was determined by quantitative real time polymerase chain reaction. Myostatin expression was significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO = 0.60 ± 0.11, control = 1.07 ± 0.11). On the other hand, rhEPO had no significant effect on the expression of TGF-β1 (rhEPO = 0.95 ± 0.14, control = 1.05 ± 0.16) and TNF-α (rhEPO = 0.73 ± 0.20, control = 1.01 ± 0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.

Show MeSH

Related in: MedlinePlus

Strength of the entire body of mdx mice treated with recombinant humanerythropoietin (rhEPO) or saline (control) for 12 weeks. P>0.05, GBStattest.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230286&req=5

f01: Strength of the entire body of mdx mice treated with recombinant humanerythropoietin (rhEPO) or saline (control) for 12 weeks. P>0.05, GBStattest.

Mentions: The muscle strength values were appropriate for the weight of the animal. There wasno change in strength between the control animals and those treated with rhEPO duringthe 12 weeks of treatment. The total force of mdx mice is reported in Figure 1.


Erythropoietin reduces the expression of myostatin in mdx dystrophic mice.

Feder D, Rugollini M, Santomauro A, Oliveira LP, Lioi VP, Santos Rd, Ferreira LG, Nunes MT, Carvalho MH, Delgado PO, Carvalho AA, Fonseca FL - Braz. J. Med. Biol. Res. (2014)

Strength of the entire body of mdx mice treated with recombinant humanerythropoietin (rhEPO) or saline (control) for 12 weeks. P>0.05, GBStattest.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230286&req=5

f01: Strength of the entire body of mdx mice treated with recombinant humanerythropoietin (rhEPO) or saline (control) for 12 weeks. P>0.05, GBStattest.
Mentions: The muscle strength values were appropriate for the weight of the animal. There wasno change in strength between the control animals and those treated with rhEPO duringthe 12 weeks of treatment. The total force of mdx mice is reported in Figure 1.

Bottom Line: EPO exerts regulatory effects in cardiac and skeletal muscles.Total strength was measured using a force transducer coupled to a computer.These results may help to clarify some of the direct actions of EPO on skeletal muscle.

View Article: PubMed Central - PubMed

Affiliation: Faculdade de Medicina do ABC, Santo André, SP, Brasil.

ABSTRACT
Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles. Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. In this study, we tested the possible therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α) was determined by quantitative real time polymerase chain reaction. Myostatin expression was significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO = 0.60 ± 0.11, control = 1.07 ± 0.11). On the other hand, rhEPO had no significant effect on the expression of TGF-β1 (rhEPO = 0.95 ± 0.14, control = 1.05 ± 0.16) and TNF-α (rhEPO = 0.73 ± 0.20, control = 1.01 ± 0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.

Show MeSH
Related in: MedlinePlus